Lucas M Donovan1, Michael Rueschman2, Jia Weng3, Nisha Basu4, Katherine A Dudley5, Jessie P Bakker6, Rui Wang7, Suzanne M Bertisch8, Sanjay R Patel9. 1. University of Washington, 1959 NE Pacific St, Seattle, WA 98195, United States. Electronic address: ldonovan@uw.edu. 2. Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States. Electronic address: mrueschman@bwh.harvard.edu. 3. Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States. Electronic address: jweng2@partners.org. 4. Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02115, United States. Electronic address: nbasu@bidmc.harvard.edu. 5. Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02115, United States. Electronic address: kdudley@bidmc.harvard.edu. 6. Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States. Electronic address: jpbakker@bwh.harvard.edu. 7. Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States. Electronic address: rwang8@partners.org. 8. Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02115, United States. Electronic address: sbertisc@bidmc.harvard.edu. 9. University of Pittsburgh, UPMC Montefiore Hospital, NW628, 3459 Fifth Avenue, Pittsburgh, PA 15213, United States. Electronic address: patelsr2@upmc.edu.
Abstract
AIMS: As recommended by current guidelines, we tested the acceptability and impact of screening patients with type 2 diabetes for obstructive sleep apnea (OSA). METHODS: In a large urban primary care practice, we instituted a telephone-based OSA screening program using a validated tool (STOP-BANG) in patients with type 2 diabetes. Patients identified as high risk were referred for diagnostic sleep testing, and those diagnosed with OSA were offered positive airway pressure (PAP) therapy. We evaluated the impact of PAP on sleep-related symptoms, glycemic control, and hospitalization rates. RESULTS: We identified 738 of 818 (90.1%) patients with type 2 diabetes as high risk for OSA. Only 29.2% (n = 213) of high risk patients were willing to undergo diagnostic sleep testing. The prevalence of OSA was 90.6% in this group, but only 66.0% of those with OSA initiated PAP. Patients with higher burden of sleep symptoms were more likely to pursue testing and initiate therapy. PAP use was associated with reduced sleep-related symptoms (mean Epworth sleepiness scale score declined from 8.8 to 7.3, p < .001), but did not impact hemoglobin A1c levels at one year (7.7-7.9%, p = .12). Changes in glycemic control and hospitalization rates did not differ from comparator groups. CONCLUSIONS: Despite a high prevalence of OSA, willingness to pursue diagnostic testing and treatment was low in an unselected type 2 diabetes population. Furthermore, glycemic control did not improve. Future screening programs should focus on patients with substantial sleep related symptoms as this group is most likely to derive benefit from treatment.
AIMS: As recommended by current guidelines, we tested the acceptability and impact of screening patients with type 2 diabetes for obstructive sleep apnea (OSA). METHODS: In a large urban primary care practice, we instituted a telephone-based OSA screening program using a validated tool (STOP-BANG) in patients with type 2 diabetes. Patients identified as high risk were referred for diagnostic sleep testing, and those diagnosed with OSA were offered positive airway pressure (PAP) therapy. We evaluated the impact of PAP on sleep-related symptoms, glycemic control, and hospitalization rates. RESULTS: We identified 738 of 818 (90.1%) patients with type 2 diabetes as high risk for OSA. Only 29.2% (n = 213) of high risk patients were willing to undergo diagnostic sleep testing. The prevalence of OSA was 90.6% in this group, but only 66.0% of those with OSA initiated PAP. Patients with higher burden of sleep symptoms were more likely to pursue testing and initiate therapy. PAP use was associated with reduced sleep-related symptoms (mean Epworth sleepiness scale score declined from 8.8 to 7.3, p < .001), but did not impact hemoglobin A1c levels at one year (7.7-7.9%, p = .12). Changes in glycemic control and hospitalization rates did not differ from comparator groups. CONCLUSIONS: Despite a high prevalence of OSA, willingness to pursue diagnostic testing and treatment was low in an unselected type 2 diabetes population. Furthermore, glycemic control did not improve. Future screening programs should focus on patients with substantial sleep related symptoms as this group is most likely to derive benefit from treatment.
Authors: Jonathan E Shaw; Naresh M Punjabi; Matthew T Naughton; Leslee Willes; Richard M Bergenstal; Peter A Cistulli; Greg R Fulcher; Glenn N Richards; Paul Z Zimmet Journal: Am J Respir Crit Care Med Date: 2016-08-15 Impact factor: 21.405
Authors: Fatima H Sert-Kuniyoshi; Ray W Squires; Yoel K Korenfeld; Virend K Somers; Snigdha Pusalavidyasagar; Sean M Caples; Lezlie L Johnson; Randal J Thomas; Francisco Lopez-Jimenez Journal: Sleep Med Date: 2011-10-05 Impact factor: 3.492
Authors: Daniel J Buysse; Lan Yu; Douglas E Moul; Anne Germain; Angela Stover; Nathan E Dodds; Kelly L Johnston; Melissa A Shablesky-Cade; Paul A Pilkonis Journal: Sleep Date: 2010-06 Impact factor: 5.849
Authors: Helaine E Resnick; Susan Redline; Eyal Shahar; Adele Gilpin; Anne Newman; Robert Walter; Gordon A Ewy; Barbara V Howard; Naresh M Punjabi Journal: Diabetes Care Date: 2003-03 Impact factor: 19.112
Authors: Paul C Myhill; Wendy A Davis; Kirsten E Peters; S A Paul Chubb; David Hillman; Timothy M E Davis Journal: J Clin Endocrinol Metab Date: 2012-09-07 Impact factor: 5.958
Authors: Terri E Weaver; Greg Maislin; David F Dinges; Thomas Bloxham; Charles F P George; Harly Greenberg; Gihan Kader; Mark Mahowald; Joel Younger; Allan I Pack Journal: Sleep Date: 2007-06 Impact factor: 5.849
Authors: Lucas M Donovan; Lan Yu; Suzanne M Bertisch; Daniel J Buysse; Michael Rueschman; Sanjay R Patel Journal: Chest Date: 2019-11-27 Impact factor: 9.410
Authors: Jack J Blanchard; Alexandra Andrea; Ryan D Orth; Christina Savage; Melanie E Bennett Journal: Psychiatry Res Date: 2020-02-07 Impact factor: 3.222
Authors: Christine E Spadola; Rebecca E Rottapel; Eric S Zhou; Jarvis T Chen; Na Guo; Sat Bir S Khalsa; Susan Redline; Suzanne M Bertisch Journal: Complement Ther Clin Pract Date: 2020-02-21 Impact factor: 2.446
Authors: Lorraine Warrington; Kate Absolom; Mark Conner; Ian Kellar; Beverly Clayton; Michael Ayres; Galina Velikova Journal: J Med Internet Res Date: 2019-01-24 Impact factor: 5.428
Authors: Michael D Faulx; Reena Mehra; Glaucylara Reis Geovanini; Shin-Ichi Ando; Michael Arzt; Luciano Drager; Michael Fu; Camilla Hoyos; Jo Hai; Juey-Jen Hwang; Remzi Karaoguz; John Kimoff; Pei-Lin Lee; Olga Mediano; Sanjay R Patel; Yüksel Peker; Jean Louis Pepin; Manuel Sanchez-de-la-Torre; Frédéric Sériès; Stefan Stadler; Patrick Strollo; A A Tahrani; Erik Thunström; Motoo Yamauchi; Susan Redline; Craig L Phillips Journal: Int J Cardiol Heart Vasc Date: 2022-07-19
Authors: Jack J Blanchard; Christina L G Savage; Ryan D Orth; Anyela M Jacome; Melanie E Bennett Journal: Front Psychiatry Date: 2020-05-28 Impact factor: 4.157